{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=37",
    "query": {
      "intervention": "Formulation #2",
      "page": 37
    },
    "page_size": 10
  },
  "pagination": {
    "page": 37,
    "page_size": 10,
    "total_count": 1745,
    "total_pages": 175,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=38&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Formulation+%232&page=36&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-05T21:20:33.270Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01692262",
      "title": "Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castrate-Resistant Prostate Cancer (mCRPC),",
        "Efficacy,",
        "Safety and Tolerability,",
        "Pharmacokinetics,",
        "Pharmacodynamics,",
        "Tumour Response."
      ],
      "interventions": [
        {
          "name": "Intermittent dosing of AZD5363",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 59,
      "start_date": "2012-11",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2014-06-19",
      "last_synced_at": "2026-11-05T21:20:33.270Z",
      "location_count": 5,
      "location_summary": "Sarasota, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 2 more",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01692262"
    },
    {
      "nct_id": "NCT06733688",
      "title": "A Study to Evaluate Oral Formulations of Tedizolid Phosphate in Healthy Participants (MK-1986-043)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Tedizolid Phosphate Oral Formulation 1 (Reference)",
          "type": "DRUG"
        },
        {
          "name": "Tedizolid Phosphate Oral Formulation 2 (Test)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "19 Years to 60 Years"
      },
      "enrollment_count": 36,
      "start_date": "2022-03-23",
      "completion_date": "2022-04-15",
      "has_results": false,
      "last_update_posted_date": "2024-12-13",
      "last_synced_at": "2026-11-05T21:20:33.270Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06733688"
    },
    {
      "nct_id": "NCT01392703",
      "title": "Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetic Study in Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Dasatinib as tablets",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib as liquid",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib as dispersed tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 141,
      "start_date": "2011-07",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2013-02-11",
      "last_synced_at": "2026-11-05T21:20:33.270Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01392703"
    },
    {
      "nct_id": "NCT02712008",
      "title": "Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Macular Edema"
      ],
      "interventions": [
        {
          "name": "REGN910-3",
          "type": "DRUG"
        },
        {
          "name": "Intravitreal Aflibercept Injection (IAI)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 302,
      "start_date": "2016-03-02",
      "completion_date": "2017-07-10",
      "has_results": true,
      "last_update_posted_date": "2018-10-03",
      "last_synced_at": "2026-11-05T21:20:33.270Z",
      "location_count": 51,
      "location_summary": "Mesa, Arizona • Tucson, Arizona • Arcadia, California + 48 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02712008"
    },
    {
      "nct_id": "NCT03529773",
      "title": "A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Tract Infections"
      ],
      "interventions": [
        {
          "name": "Formulation A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Formulation B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 1235,
      "start_date": "2018-04-18",
      "completion_date": "2020-12-28",
      "has_results": true,
      "last_update_posted_date": "2022-03-03",
      "last_synced_at": "2026-11-05T21:20:33.270Z",
      "location_count": 40,
      "location_summary": "Mobile, Alabama • Anaheim, California • La Mesa, California + 30 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Redding",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03529773"
    },
    {
      "nct_id": "NCT00689481",
      "title": "Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "U0267 Foam",
          "type": "DRUG"
        },
        {
          "name": "Vehicle foam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stiefel, a GSK Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 323,
      "start_date": "2008-03",
      "completion_date": "2008-10",
      "has_results": true,
      "last_update_posted_date": "2016-10-07",
      "last_synced_at": "2026-11-05T21:20:33.270Z",
      "location_count": 12,
      "location_summary": "Mobile, Alabama • Fremont, California • Ormond Beach, Florida + 9 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Ormond Beach",
          "state": "Florida"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00689481"
    },
    {
      "nct_id": "NCT02930694",
      "title": "A Study to Evaluate the Bioavailability, Safety and Tolerability of a Solid Dosage Formulation Relative to a Suspension of JNJ-54175446 in Healthy Male and Female Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "JNJ-54175446 (capsule)",
          "type": "DRUG"
        },
        {
          "name": "JNJ-54175446 (suspension)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2016-10",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2017-02-16",
      "last_synced_at": "2026-11-05T21:20:33.270Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02930694"
    },
    {
      "nct_id": "NCT03770065",
      "title": "Exploratory Study on Two Different Doses of VML-0001 on the Effects on Vaginal pH in Healthy Post-Menopausal Women",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Vaginal Atrophy"
      ],
      "interventions": [
        {
          "name": "VML-0001",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Viramal Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "45 Years and older · Female only"
      },
      "enrollment_count": 14,
      "start_date": "2018-11-19",
      "completion_date": "2020-04-08",
      "has_results": false,
      "last_update_posted_date": "2020-10-06",
      "last_synced_at": "2026-11-05T21:20:33.270Z",
      "location_count": 1,
      "location_summary": "Huntsville, Alabama",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03770065"
    },
    {
      "nct_id": "NCT03858036",
      "title": "Corneal Collagen Cross-Linking (CXL) Performed With \"Epi-ON\" Versus \"Epi-OFF\" in Eyes With Keratoconus and Other Corneal Ectatic Disorders",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Keratoconus",
        "Ectasia"
      ],
      "interventions": [
        {
          "name": "Ricrolin+",
          "type": "DRUG"
        },
        {
          "name": "VEGA UV-A system",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Center for Sight, Sacramento, CA",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 550,
      "start_date": "2019-03-08",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2019-02-28",
      "last_synced_at": "2026-11-05T21:20:33.270Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03858036"
    },
    {
      "nct_id": "NCT01519011",
      "title": "Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myelodysplastic Syndromes",
        "Leukemia, Myelomonocytic, Chronic",
        "Leukemia, Myeloid, Acute"
      ],
      "interventions": [
        {
          "name": "oral azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2012-02-07",
      "completion_date": "2015-05-12",
      "has_results": false,
      "last_update_posted_date": "2019-11-12",
      "last_synced_at": "2026-11-05T21:20:33.270Z",
      "location_count": 8,
      "location_summary": "La Jolla, California • Denver, Colorado • Las Vegas, Nevada + 5 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01519011"
    }
  ]
}